Prescription low-T Supplement Lawsuit News
A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff’s lawyer said in a statement.
READ MORE at Reuters
AbbVie must pay $150 million to an Oregon man who accused the pharmaceutical company of misrepresenting the safety risks of its AndroGel drug to treat low testosterone, a federal jury decided Monday in Chicago.
READ MORE at Chicago Tribune
AbbVie’s former blockbuster testosterone-replacement treatment AndroGel will be at the center of a class action lawsuit set to go to trial this year, alleging, in short, that previously healthy men suffered heart attacks and other side effects after taking the product.
READ MORE at FiercePharma